Protein Is Identified As An Antigen, E.g., Immunogenic Carriers, Etc. Patents (Class 530/403)
  • Patent number: 9244083
    Abstract: Compounds include carbamate derivatives of vitamin D including vitamin D3and vitamin D2. The compounds are useful in methods and kits for determining the presence and/or amount of vitamin D including vitamin D analogs and metabolites thereof in a sample suspected of containing the same.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: January 26, 2016
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Zhu Teng, Roland Janzen, Martin A. Drinan
  • Patent number: 9163091
    Abstract: Compositions and methods for making and using anti-LPA agents, for example, monoclonal antibodies, are described. Variable domain and complementarity determining region amino acid sequences of several monoclonal antibodies against LPA are disclosed, as is a consensus anti-LPA monoclonal antibody variable domain sequence.
    Type: Grant
    Filed: March 18, 2009
    Date of Patent: October 20, 2015
    Assignee: Lpath, Inc.
    Inventors: Roger A. Sabbadini, William A. Garland, James Stephen Swaney, Rosalia Matteo, Gordon Mills, Jonathan Michael Wojciak
  • Patent number: 9125847
    Abstract: The present invention is directed to methods of producing conjugates of A? peptide immunogens with protein/polypeptide carrier molecules, which are useful as immunogens, wherein peptide immunogens are conjugated to protein carriers via activated functional groups on amino acid residues of the carrier or of the optionally attached linker molecule, and wherein any unconjugated reactive functional groups on amino acid residues are inactivated via capping, thus retaining the immunological functionality of the carrier molecule, but reducing the propensity for undesirable reactions that could render the conjugate less safe or effective. Furthermore, the invention also relates to such immunogenic products and immunogenic compositions containing such immunogenic products made by such methods.
    Type: Grant
    Filed: February 14, 2012
    Date of Patent: September 8, 2015
    Assignees: Janssen Sciences Ireland UC, Wyeth LLC
    Inventors: Rasappa G. Arumugham, A. Krishna Prasad, Michael Hagen
  • Patent number: 9089510
    Abstract: The present invention is directed to methods of producing conjugates of A? peptide immunogens with protein/polypeptide carrier molecules, which are useful as immunogens, wherein peptide immunogens are conjugated to protein carriers via activated functional groups on amino acid residues of the carrier or of the optionally attached linker molecule, and wherein any unconjugated reactive functional groups on amino acid residues are inactivated via capping, thus retaining the immunological functionality of the carrier molecule, but reducing the propensity for undesirable reactions that could render the conjugate less safe or effective. Furthermore, the invention also relates to such immunogenic products and immunogenic compositions containing such immunogenic products made by such methods.
    Type: Grant
    Filed: July 7, 2011
    Date of Patent: July 28, 2015
    Assignees: Janssen Sciences Ireland UC, Wyeth LLC
    Inventors: Rasappa G. Arumugham, A. Krishna Prasad, Michael Hagen
  • Publication number: 20150132367
    Abstract: The present invention relates to the use of Yersinia outer protein M (YopM), a YopM fragment, or a YopM variant, which is capable of autopenetrating the cell membrane and of integrating into the cell cytosol without the requirement of additional factors for delivering a cargo molecule across the membrane to the cytosol of a cell. The present invention also relates to a pharmaceutical composition comprising YopM, a YopM fragment, or a YopM variant being capable of autopenetrating the cell membrane and of integrating into the cell cytosol without the requirement of additional factors for the regulation of inflammatory reactions of the immune system and the treatment of diseases caused by autoimmunity of the host. The present invention further relates to a YopM fragment or variant, which is capable of autopenetrating the cell membrane and of integrating into the cell cytosol without the requirements of additional factors as well as such proteins or YopM linked to a cargo molecule.
    Type: Application
    Filed: September 22, 2014
    Publication date: May 14, 2015
    Inventors: CHRISTIAN RUETER, Gerhard Heusipp, Alexander M. Schmidt
  • Publication number: 20150118698
    Abstract: A method of bioassay for the quantification of peptide fragments comprising a neo-epitope formed by cleavage ofmimecan, a protein of an atherosclerotic plaque, by a proteinase, said comprises contacting a sample such as urine or serum with an antibody reactive with the neo-epitope and determining the level of binding of said immunological binding partner to peptide fragments in said sample. The assay is predictive of risk of cardiovascular disease events.
    Type: Application
    Filed: May 4, 2012
    Publication date: April 30, 2015
    Applicant: Nordic Biociences A/S
    Inventors: Natas[c]ha Barascuk Michaelsen, Federica Genovese, Morten Karsdal, Diana Julie Leeming
  • Publication number: 20150098961
    Abstract: The inventive subject matter relates to a recombinant polypeptide construct comprising enterotoxigenic Escherichia coli fimbrial subunits. The recombinant polypeptide constructs comprise multiple subunits to the same or different ETEC fimbrial types. The constructs are useful for inclusion in immunogenic formulations for the inductin of immunity against entertoxigenic Escherichia coli. The inventive subject matter also relates to the use of the recombinant polypeptide constructs in induce anti-enterotoxigenic Escherichia coli.
    Type: Application
    Filed: October 8, 2013
    Publication date: April 9, 2015
    Inventor: Stephen Savarino
  • Publication number: 20150093406
    Abstract: The present application is related to a modified protein comprising a protein having a coiled coil domain and a peptide having the sequence such as shown in SEQ ID NO 1: ZXBBBBZ that is linked to the coiled coil domain wherein: Z is any amino acid or is absent; X is any amino acid; B is an arginine (R) or a lysine (K). Said modified protein is in particular an antigen or a carrier protein, associated to an antigen. This modified protein has an increased affinity for negatively charged polymers such as nucleic acids or heparin, and shows an increased immunogenicity.
    Type: Application
    Filed: December 15, 2014
    Publication date: April 2, 2015
    Inventors: Judith DEL CAMPO ASCARATEIL, Imene TURKI HANI, Fergal HILL
  • Patent number: 8986704
    Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: March 24, 2015
    Assignee: Valneva Austria GmbH
    Inventors: Pär Comstedt, Markus Hanner, Urban Lundberg, Andreas Meinke, Wolfgang Schueler, Benjamin Wizel
  • Publication number: 20150080558
    Abstract: The present invention relates to chromatography matrices including ligands based on one or more domains of immunoglobulin-binding proteins such as, Staphylococcus aureus Protein A (SpA), as well as methods of using the same.
    Type: Application
    Filed: November 6, 2014
    Publication date: March 19, 2015
    Inventors: Shari Spector, Robert Smith, Joe Orlando, Nanying Bian
  • Patent number: 8980646
    Abstract: Improved methods for the production, selection and inhibition of catalytic and covalent antibodies are disclosed.
    Type: Grant
    Filed: March 26, 2004
    Date of Patent: March 17, 2015
    Assignee: Paul, Sudhir
    Inventors: Sudhir Paul, Yasuhiro Nishiyama
  • Patent number: 8974797
    Abstract: The invention provides expression vectors and virus-like particles (VLPs) containing Newcastle Disease Virus Sequences in combination with sequences encoding proteins of interest. The vectors are useful in, for example, generating virus-like particles (VLPs) that contain proteins of interest. In one embodiment, the expressed VLPs elicit an immune response by an animal host against the protein. The invention's VLPs are useful as, for example, vaccines.
    Type: Grant
    Filed: January 30, 2009
    Date of Patent: March 10, 2015
    Assignee: University of Massachusetts
    Inventor: Trudy Morrison
  • Publication number: 20150064198
    Abstract: The invention is directed to compositions and methods for generating or enhancing the immune system of a patient against infection by a pathogen, and in particular MTB. Compositions of the invention contain one or more non-naturally occurring antigens that generate an effective cellular or humoral immune response to MTB and/or antibodies that are specifically reactive to mycolic acid or to the surface of MTB. The greater activity of the immune system generated by a vaccine of the invention involve an conjugation of peptides to increase in the generation of memory T cells that provide for a greater and/or longer lived or extended response to an MTB infection. Preferably a response involves an increased generation of antibodies that enhance immunity against MTB infection and promote an enhanced phagocytic response.
    Type: Application
    Filed: August 29, 2014
    Publication date: March 5, 2015
    Inventors: Gerald W. Fischer, Luke T. Daum, Clara Jebet Sei
  • Publication number: 20150037371
    Abstract: The invention provides a method of enhancing the immunogenicity of pathogenic antigens by removing or disrupting intrachain disulfide bonds responsible for maintaining tertiary protein structure. Removal of one or more disulfide bonds can increase the titer of neutralizing antibodies to a pathogen (e.g., a bacterium, fungus, virus, or parasite). The invention also features vaccines, expression vectors, and methods for the manufacture and use thereof.
    Type: Application
    Filed: October 14, 2014
    Publication date: February 5, 2015
    Inventor: Samuel J. LANDRY
  • Publication number: 20150037826
    Abstract: The invention relates to standards for quantifying pathogenic aggregates or oligomers of endogenous proteins which characterize a protein aggregation disease, amyloid degeneration or protein misfolding diseases and use of these standards for quantifying these pathogenic aggregates or oligomers.
    Type: Application
    Filed: December 21, 2012
    Publication date: February 5, 2015
    Inventors: Dieter Willbold, Susanne Aileen Funke
  • Patent number: 8946392
    Abstract: The present invention comprises novel conjugates and immunogens derived from gemcitabine and unique antibodies generated by using gemcitabine linked immunogens, which conjugates immunogens and antibodies, are useful in immunoassays for the quantification and monitoring of gemcitabine in biological fluids.
    Type: Grant
    Filed: June 14, 2011
    Date of Patent: February 3, 2015
    Assignee: Saladax Biomedical Inc.
    Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Howard Sard, Christopher Spedaliere
  • Publication number: 20150017201
    Abstract: The present invention provides DNA-nanostructures comprising and at least one targeting moiety, wherein the at least one targeting moiety is linked to the DNA-nanostructure; and wherein the at least one targeting moiety is nicotine or a nicotine analogue. These compounds elicit an immunogenic response in individuals and are useful as vaccines for ameliorating nicotine dependence.
    Type: Application
    Filed: March 13, 2014
    Publication date: January 15, 2015
    Inventors: Yung Chang, Hao Yan, Sidney Hecht, Paul Pentel, Xiaowei Liu, Rumit Maini
  • Patent number: 8927290
    Abstract: Provided herein are compositions comprising native and denatured human leukocyte antigens (HLA) and methods of making said compositions. Also provided herein are methods and kits for the detection of antibodies to native HLAs.
    Type: Grant
    Filed: February 16, 2011
    Date of Patent: January 6, 2015
    Assignee: One Lambda, Inc.
    Inventors: Adam Idica, Chun-Tsan Deng, Paul I. Terasaki
  • Patent number: 8927225
    Abstract: Disclosed is an assay (method) to quantify the amounts of catecholamine-O-methyltransferase (COMT) protein in samples, such as extracts from cell cultures, body fluids, tissues, and environmental samples. It uses novel agents (anti-NE, COMT-NE, or COMT-epitope-NE) in combination with two previously described agents (anti-COMT and COMT) in a competitive ELISA system to achieve this aim.
    Type: Grant
    Filed: September 8, 2009
    Date of Patent: January 6, 2015
    Assignee: The University of Hong Kong
    Inventors: Shu Leong Ho, Wing Lok Ho, David Boyer Ramsden
  • Patent number: 8927495
    Abstract: Adrenocortical disease (ACD) in ferrets develops as a result of the effect of increased concentration of Luteinizing Hormone (LH) on adrenal LH receptors. This increase in LH often results from the neutering of male or female ferrets. Neutered ferrets have no negative feedback of the ovarian or testicular hormone and as a result LH is elevated 3 to 10 times normal. Elevated LH may be prevented and/or treated by injection of GnRH vaccine. Administration of GnRH produces antibodies to endogenous GnRH. The GnRH-anti-GnRH immune-complex is ineffective in stimulating the release of LH and FSH in the anterior pituitary resulting drop in concentration of LH in the systemic circulation. This reduction in LH significantly reduces the occurrence or clinical symptoms of ACD therein. Moreover, treatment of ferrets with the GnRH provides long term relief from ACD for a period of a year or more.
    Type: Grant
    Filed: May 24, 2012
    Date of Patent: January 6, 2015
    Assignees: The United States of America as represented by the Secretary of Agriculture
    Inventors: Lowell A. Miller, Robert A. Wagner
  • Patent number: 8912010
    Abstract: Provided are a base plate and a method for thyroxine immunoassay, which are capable of decreasing the signal change rate caused by temperature change in a high-sensitivity immunoassay method for thyroxine. A base plate for thyroxine immunoassay which has a conjugate of thyroxine or a derivative thereof and albumin immobilized thereon, and in which the ratio of the molecule number of thyroxine or a derivative thereof to the molecule number of albumin in the immobilized conjugate, is disclosed.
    Type: Grant
    Filed: September 11, 2012
    Date of Patent: December 16, 2014
    Assignee: FUJIFILM Corporation
    Inventors: Noriyuki Kasagi, Junichi Katada, Tadahiro Matsuno
  • Publication number: 20140356384
    Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.
    Type: Application
    Filed: August 15, 2014
    Publication date: December 4, 2014
    Inventors: Jeffrey A. Hubbell, Stéphane Kontos, Karen Y. Dane
  • Patent number: 8895020
    Abstract: Single chain trimer (SCT) molecules are disclosed, comprising an MHC antigen peptide sequence, a ?2-microglobulin sequence and a full-length MHC class I heavy chain sequence, joined by linker sequences. Further described are nucleic acids encoding single chain trimers. Methods for expansion of antigen-specific T cell populations using single chain trimer molecules are also disclosed. In some configurations, these methods comprise co-culturing, in a first stage, CD8+ T cells from a donor with antigen presenting cells comprising an MHC antigen peptide, and co-culturing, in a second stage, the CD8+ T cells with cells comprising an SCT which has an MHC antigen peptide sequence identical to the sequence of the antigen peptide in the first stage. The methods can provide 10,000-100,000 fold expansion of antigen-specific CD8+ T cells within about 28 days after establishing culture, and can yield over 1 billion antigen-specific CD8+ T cells expanded from an individual donor.
    Type: Grant
    Filed: April 4, 2006
    Date of Patent: November 25, 2014
    Assignee: Washington University
    Inventors: Ted Hansen, Yik Yeung Lawrence Yu
  • Patent number: 8852605
    Abstract: The disclosure pertains to conjugates of the capsular polysaccharide of Vibrio cholerae O139, or a structurally and/or immunologically related oligo- or poly-saccharide, and a carrier. These conjugates are useful as pharmaceutical compositions and/or vaccines to induce serum antibodies which have bactericidal (vibriocidal) activity against V. cholerae, in particular V. cholerae O139, and are useful to prevent, treat and/or reduce the severity of disease caused by V. cholerae infection, such as cholera. The present disclosure also relates to diagnostic tests for V. cholerae infection, and/or cholera caused by V. cholerae infection, using one or more of the oligo- or poly-saccharide-carrier conjugates or antibodies described above.
    Type: Grant
    Filed: April 3, 2007
    Date of Patent: October 7, 2014
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Shousun Chen Szu, Zuzana Kossaczka, John B. Robbins
  • Publication number: 20140275478
    Abstract: The present invention describes an efficient vaccine against a Chlamydia trachomatis (Ct). The vaccine is based on recombinant fusion molecules that are capable of generating a high titered neutralizing antibody response that is protective against various Ct serovars. Our invention furthermore describe the combination of these antibody promoting fragments with Ct antigens that are targets for T cells with the aim to provide a vaccine that activate both arms of the immune system.
    Type: Application
    Filed: March 17, 2014
    Publication date: September 18, 2014
    Applicant: Statens Serum Institut
    Inventors: Frank Follmann, Ida Rosenkrands, Anja Olsen, Peter Andersen
  • Patent number: 8828665
    Abstract: Compounds and methods for use in detecting gabapentin in a sample suspected of containing gabapentin are disclosed. Gabapentin derivatives are used to produce gabapentin conjugates. A gabapentin-immunogenic carrier conjugate may be used as an immunogen for the preparation of an anti-gabapentin antibody. A gabapentin-detectable label may be used in a signal producing system in gabapentin assays.
    Type: Grant
    Filed: February 15, 2008
    Date of Patent: September 9, 2014
    Assignee: ARK Diagnostics, Inc.
    Inventors: Johnny Jose Valdez, Byung Sook Moon, Michael Kevin Helms, Alejandro A. Orozco
  • Publication number: 20140221628
    Abstract: A DNA vaccine comprising hyperglycosylated mutant HA gene, which is derived from avian influenza virus, is provided. A DNA vaccine composition comprising: (a) the DNA vaccine; and (b) a booster is also provided. An influenza virus-like particle comprising adjuvant-fused M2 protein is further provided.
    Type: Application
    Filed: April 8, 2014
    Publication date: August 7, 2014
    Applicant: NATIONAL TSING HUA UNIVERSITY
    Inventors: Suh-Chin Wu, Wen-Chun Liu, Hung-Ju Wei
  • Patent number: 8796429
    Abstract: Compositions and methods for producing monoclonal antibodies and their derivatives reactive against bioactive lipid targets are described. These compositions include derivatized lipids, each of which comprises a bioactive lipid that having a polar head group and at least one hydrocarbon chain (e.g., a lysolipid such as lysophosphatidic acid or sphingosine-1-phosphate) in which a carbon atom has been derivatized with a pendant reactive group; immunogens made by linking a derivatized lipid to a carrier moiety (e.g., a carrier protein, polyethylene glycol, colloidal gold, alginate, or a silicone bead); monoclonal antibodies and derivatives produced by immunizing an animal with such an immunogen; and therapeutic and diagnostic compositions containing such antibodies and antibody derivatives.
    Type: Grant
    Filed: May 30, 2007
    Date of Patent: August 5, 2014
    Assignee: Lpath, Inc.
    Inventors: Roger A. Sabbadini, William A. Garland, Genevieve Hansen
  • Patent number: 8771702
    Abstract: The present invention provides recombinant proteins or peptides comprising a mutated listeriolysin O (LLO) protein or fragment thereof, comprising a substitution or internal deletion of the cholesterol-binding domain or a portion thereof, fusion proteins or peptides comprising same, nucleotide molecules encoding same, and vaccine vectors comprising or encoding same. The present invention also provides methods of utilizing recombinant proteins, peptides, nucleotide molecules, and vaccine vectors of the present invention to induce an immune response to a peptide of interest.
    Type: Grant
    Filed: June 23, 2008
    Date of Patent: July 8, 2014
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Yvonne Paterson, Paulo Cesar Maciag
  • Patent number: 8771972
    Abstract: Novel conjugates and immunogens derived from clozapine and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of clozapine in biological fluids.
    Type: Grant
    Filed: July 19, 2011
    Date of Patent: July 8, 2014
    Assignee: Saladax Biomedical Inc.
    Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Howard Sard, Christopher Spedaliere
  • Patent number: 8753623
    Abstract: The present invention discloses isolated peptides encoding an antigen or fragments thereof from the N-terminus of hemagglutinin protein of influenza, methods for isolating such antigens and specific uses thereof. The peptide can be used as a vaccine to generate an antibody response that neutralizes influenza infectivity against a variety of influenza strains.
    Type: Grant
    Filed: April 29, 2010
    Date of Patent: June 17, 2014
    Inventors: Runtao He, Xuguang Li, Gary Van Domselaar
  • Patent number: 8735556
    Abstract: The invention relates to the detection and quantification of carbamazepine drugs and their metabolites. The invention is underpinned by novel polyclonal antibodies with unique binding properties which enable immunoassay methods and kits for various applications.
    Type: Grant
    Filed: June 18, 2012
    Date of Patent: May 27, 2014
    Assignee: Randox Laboratories Limited
    Inventors: Elouard Benchikh, Andrew Philip Lowry, Ivan McConnell, Peter Stephen Fitzgerald
  • Publication number: 20140134199
    Abstract: Provided in the present invention are a diphtheria toxin non-toxic mutant CRM197 or a fragment thereof as an adjuvant in a fusion protein and the use thereof to enhance the immunogenicity of a target protein fused therewith, for example, an HEV capsid protein, or an influenza virus M2 protein or an immunogenic fragment thereof. Also provided is a method for enhancing the immunogenicity of a target protein, comprising the fusion expression of the CRM197 or the fragment thereof with the target protein to form a fusion protein. Further provided is a fusion protein comprising the CRM197 or the fragment thereof and a target protein, the CRM197 or the fragment thereof enhancing the immunogenicity of the target protein. The present invention also provides an isolated nucleic acid encoding the fusion protein, a construct and a vector comprising said nucleic acid, and a host cell comprising the nucleic acid.
    Type: Application
    Filed: June 1, 2012
    Publication date: May 15, 2014
    Applicants: XIAMEN INNOVAX BIOTECH CO., LTD., XIAMEN UNIVERSITY
    Inventors: Shaowei Li, Cuiling Song, Chunyan Yang, Ying Gu, Wenxin Luo, Ningshao Xia
  • Patent number: 8709830
    Abstract: The present invention provides methods, compositions, and kits useful in preparing labeled molecules, which are useful in the detection of binding partners.
    Type: Grant
    Filed: March 16, 2012
    Date of Patent: April 29, 2014
    Assignee: Biotium, Inc.
    Inventors: Fei Mao, Wai-Yee Leung, Ching-Ying Cheung, Hye Eun Hoover
  • Patent number: 8703722
    Abstract: The present invention relates to blood group A/B/H determinant on Type 1 Core glycosphingolipids chains as recognition point for the FedF protein of F18-fimbriated Enterotoxigenic and verotoxinogenic Escherichia coli and the use of compounds comprising such determinants for the treatment of F18+ E. coli infections in pigs and in screening methods.
    Type: Grant
    Filed: September 30, 2009
    Date of Patent: April 22, 2014
    Assignee: Universiteit Gent
    Inventors: Annelies Coddens, Eric Cox, Susann Eva Teneberg
  • Patent number: 8703914
    Abstract: Alternative and improved approaches to the heterologous expression of the proteins of Neisseria meningitidis and Neisseria gonorrhoeae. These approaches typically affect the level of expression, the ease of purification, the cellular localization, and/or the immunological properties of the expressed protein.
    Type: Grant
    Filed: December 29, 2011
    Date of Patent: April 22, 2014
    Assignee: Novartis AG
    Inventors: Maria Beatrice Arico, Maurizio Comanducci, Cesira Galeotti, Vega Masignani, Marizia Monica Guiliani, Mariagrazia Pizza
  • Patent number: 8685662
    Abstract: The present invention pertains to a method for in vitro prognosticating and/or diagnosing cerebral cerebral malaria, wherein said method comprises a step of detecting non-erythroid spectrin or fragments thereof, and/or antibodies directed against non-erythroid spectrin, in a biological sample. Reagents and kits for performing this method are also disclosed.
    Type: Grant
    Filed: March 30, 2007
    Date of Patent: April 1, 2014
    Assignees: Institut Pasteur, Universite Pierre et Marie Curie (Paris 6)
    Inventors: Sylviane Pied, Vincent Guiyedi, Pierre-André Cazenave, Maryvonne Kombila, Youri Chanseaud
  • Patent number: 8669046
    Abstract: Antibodies that specifically bind to a peptide having an amino acid sequence as found at the N-terminus of the HA2 fusion peptide of the influenza A virus may be raised by inoculating a mammal with a conjugate of the peptide. In one embodiment, the conjugate comprises the peptide linked to a spacer (e.g. 6-aminocaproic acid) and a carrier protein (e.g. KLH). The antibodies may be used as a universal reagent for detecting HA proteins of influenza viruses. The antibodies are useful as versatile reagents for laboratory research and vaccine potency determination, especially in the event of pandemic influenza outbreaks.
    Type: Grant
    Filed: March 10, 2009
    Date of Patent: March 11, 2014
    Inventors: Xuguang (Sean) Li, Runtao He, Gary Van Domselaar
  • Publication number: 20140024056
    Abstract: The present invention provides compounds that are surrogates of post-translationally modified proteins and uses thereof. Numerous diseases are associated with post-translationally modified proteins that are difficult to obtain in homogenous form and in quantities needed for immunization and use as convenient standards, calibrators, and/or reference compounds that facilitate the detection and analysis of endogenous post-translationally modified proteins. The surrogate compounds of the invention typically comprise antigenic epitopes (one of which carries a post-translational modification) that are tethered by a flexible and hydrophilic linker. The resulting compound behaves like a surrogate of the post-translationally modified protein because it preserves the character of the included antigens and allows recognition by specific antibodies targeting the individual antigens.
    Type: Application
    Filed: February 10, 2012
    Publication date: January 23, 2014
    Applicant: President and Fellows of Harvard College
    Inventors: Michael Chorev, Joes A. Halperin
  • Patent number: 8618265
    Abstract: A method for performing a multiplexed diagnostic assay, such as for two or more different targets in a sample, is described. One embodiment comprised contacting the sample with two or more specific binding moieties that bind specifically to two or more different targets. The two or more specific binding moieties are conjugated to different haptens, and at least one of the haptens is an oxazole, a pyrazole, a thiazole, a nitroaryl compound other than dinitrophenyl, a benzofurazan, a triterpene, a urea, a thiourea, a rotenoid, a coumarin, a cyclolignan, a heterobiaryl, an azo aryl, or a benzodiazepine. The sample is contacted with two or more different anti-hapten antibodies that can be detected separately. The two or more different anti-hapten antibodies may be conjugated to different detectable labels.
    Type: Grant
    Filed: March 2, 2010
    Date of Patent: December 31, 2013
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Jerome W. Kosmeder, Mark Lefever, Donald Johnson, Michael Farrell, Zhanna Zhilina, Christopher Bieniarz
  • Patent number: 8617566
    Abstract: The present invention relates to novel uses of a construct consisting of virus-like particle (VLP) structure chemically coupled to a fragment of the A beta-1-42 peptide and its pharmaceutically acceptable salts (hereinafter CONSTRUCT), in particular to dosage regimens, modes of and dosage forms for the administration of a CONSTRUCT for the treatment of patients suffering from dementia, in particular dementia of the Alzheimer's type.
    Type: Grant
    Filed: May 13, 2013
    Date of Patent: December 31, 2013
    Assignee: Novartis AG
    Inventors: Ana Graf, Matthias Staufenbiel, Thomas Blaettler, Paolo Paganetti
  • Patent number: 8603483
    Abstract: The invention relates to conjugates of anti-integrin specific antibodies with cytotoxic compounds, the synthesis, selection, and use of such conjugates for use in cancer therapy or other diseases mediated by cell proliferation, cell migration, or inflammation and which pathology involves angiogenesis or neovascularization of new tissue. In addition the invention relates to combination therapy of such diseases wherein the treatment comprises use of said conjugates in combination with one or more other treatment modalities including but not limited to: chemotherapy, surgery or radiation therapy. The preferred conjugates contain maytansinoid compounds linked to the antibody by a disulfide linkage, and preferred chemotherapeutic agents are doxorubicin, a taxane, a camptothecin, a podophyllotoxin, a nucleoside analog, or a pyrimidine analog.
    Type: Grant
    Filed: November 30, 2005
    Date of Patent: December 10, 2013
    Assignees: Janssen Biotech, Inc., Immunogen, Inc.
    Inventors: Qiming Chen, Mohit Trikha, Robert J. Lutz, Rita M. Steeves, Godfrey Amphlett
  • Patent number: 8597656
    Abstract: The present invention relates to a process for producing immunogenic polypeptides, comprising reducing disulfide bonds and blocking the resulting free thiol group with a blocking agent. The immunogenic peptides comprise a fragment of MAGE A3.
    Type: Grant
    Filed: December 13, 2011
    Date of Patent: December 3, 2013
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventors: Teresa Cabezon Silva, Joseph Cohen, Moncef Mohamed Slaoui, Carlota Vinals Bassols
  • Publication number: 20130315949
    Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses.
    Type: Application
    Filed: December 7, 2012
    Publication date: November 28, 2013
    Applicant: Cytos Biotechnology AG
    Inventors: Wolfgang A. RENNER, Martin Bachmann, Alain Tissot, Patrick Maurer, Franziska Lechner, Peter Sebbel, Christine Piossek
  • Publication number: 20130317205
    Abstract: The present invention provides methods of making engineered viral proteins and protein complexes that are useful as vaccine immunogens, engineered viral proteins and protein complexes made using such methods, and pharmaceutical compositions comprising such engineered viral proteins and protein complexes. Such engineered viral proteins and protein complexes may comprise one or more cross-links that stabilize the conformation of an antibody epitope, such as a quaternary neutralizing antibody, and may exhibit an enhanced ability to elicit a protective immune response when administered to a subject as a component of a vaccine.
    Type: Application
    Filed: May 9, 2013
    Publication date: November 28, 2013
    Inventor: Christopher Marshall
  • Patent number: 8592564
    Abstract: Generally, the present invention relates to lamotrigine analogs that have substituents at the triazine 3-position and on the benzene 4-position and 5-position. The lamotrigine analogs can include immunogenic moieties that can be used to prepare anti-lamotrigine antibodies, or antigenic moieties that can be used in immunodiagnostic assays for lamotrigine. Also, the lamotrigine analog can include tracer moieties for detecting the presence or amount of the analog during an immunodiagnostic assay. Additionally, the lamotrigine analogs can be used in immunodiagnostic assays to compete with lamotrigine for binding with anti-lamotrigine antibodies.
    Type: Grant
    Filed: January 25, 2010
    Date of Patent: November 26, 2013
    Assignee: Seradyn, Inc.
    Inventors: Anlong Ouyang, Lili Arabshahi, Mark Roberts, Melissa Wall
  • Publication number: 20130288274
    Abstract: The present invention provides a method for determining whether a subject is suffering from celiac disease by contacting a sample of bodily fluid from the subject, with an antigen formed from a hexamer of a gliadin fusion protein immobilized on a solid support. The gliadin fusion protein of the antigen includes a recombinant deamidated gliadin linked to a tag such as Glutathione-S transferase (GST) protein. The antigen is prepared by immobilizing the gliadin fusion protein on the solid support. The antigen can further include tissue Transglutaminase (tTG) cross-linked to the gliadin fusion protein. When tTG is present, the tTG and recombinant deamidated gliadin are mixed together prior to immobilization to the solid phase.
    Type: Application
    Filed: December 3, 2012
    Publication date: October 31, 2013
    Inventor: Bio Rad Laboratories, Inc.
  • Patent number: 8563327
    Abstract: The present invention provides, as a novel diagnosis marker for type 1 diabetes mellitus, a type 1 diabetes mellitus diagnostic composition comprising alanyl-tRNA synthetase, glycyl-tRNA synthetase, asparaginyl-tRNA synthetase, or tryptophanyl-tRNA synthetase, a diagnostic kit comprising the same, and a diagnostic method using the same. The composition, the kit, and the method, according to the present invention, may be used for early diagnosis and confirmed diagnosis of type 1 diabetes mellitus because type 1 diabetes mellitus can be easily diagnosed from a patient sample.
    Type: Grant
    Filed: August 5, 2011
    Date of Patent: October 22, 2013
    Assignees: Seoul National University Hospital, SNU R&DB Foundation
    Inventors: Sang Gyu Park, Kyong Soo Park, Sunghoon Kim
  • Patent number: 8557601
    Abstract: The present invention provides luminescent complexes between a lanthanide ion and an organic ligand which contains 1,2-hydroxypyridinone units. The complexes of the invention are stable in aqueous solutions and are useful as molecular probes, for example in medical diagnostics and bioanalytical assay systems. The invention also provides methods of using the complexes of the invention.
    Type: Grant
    Filed: July 10, 2007
    Date of Patent: October 15, 2013
    Assignee: The Regents of the University of California
    Inventors: Kenneth N. Raymond, Jide Xu, Evan G. Moore, Eric J. Werner
  • Publication number: 20130217044
    Abstract: Disclosed are a protein and a gene each of which is a factor involved in latent infection with a herpesvirus. An antibody against the factor was detected in approximately 50% of patients suffering from mental disorders, whereas the antibody was hardly detected in healthy persons. Further, a mouse having SITH-1 introduced therein developed a mental disorder such as a manic-depressive illness or depression-like disorder. Based on these findings, it is possible to provide a method for objectively determining a mental disorder and an animal model of a mental disorder.
    Type: Application
    Filed: January 2, 2013
    Publication date: August 22, 2013
    Applicants: JAPAN TOBACCO INC., VIRUS IKAGAKU KENKYUSHO INC.
    Inventors: Virus Ikagaku Kenkyusho Inc., Japan Tobacco Inc.